A number of other research firms also recently weighed in on EYPT. ValuEngine upgraded Eyepoint Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, May 29th. Zacks Investment Research cut Eyepoint Pharmaceuticals from a buy rating to a hold rating in a report on Monday, June 4th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Eyepoint Pharmaceuticals currently has an average rating of Buy and a consensus target price of $4.90.
EYPT traded down $0.08 during trading on Thursday, reaching $2.24. The stock had a trading volume of 2,100 shares, compared to its average volume of 196,604. The company has a market capitalization of $114.54 million, a price-to-earnings ratio of -4.33 and a beta of 0.97. The company has a debt-to-equity ratio of 1.57, a current ratio of 0.83 and a quick ratio of 0.83. Eyepoint Pharmaceuticals has a 1-year low of $0.93 and a 1-year high of $2.88.
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC bought a new position in shares of Eyepoint Pharmaceuticals in the second quarter valued at $2,339,000. BlackRock Inc. bought a new position in shares of Eyepoint Pharmaceuticals in the second quarter valued at $304,000. Bard Associates Inc. bought a new position in shares of Eyepoint Pharmaceuticals in the second quarter valued at $189,000. Essex Investment Management Co. LLC bought a new position in shares of Eyepoint Pharmaceuticals in the second quarter valued at $170,000. Finally, Creative Planning bought a new position in shares of Eyepoint Pharmaceuticals in the second quarter valued at $162,000. 62.93% of the stock is currently owned by institutional investors.
Eyepoint Pharmaceuticals Company Profile
EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis.
Further Reading: Penny Stocks
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.